These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Benzinga

08/14

Altimmune, Inc. (NASDAQ:ALT) posted a loss for the second quarter on Tuesday.

The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.

“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”

Altimmune shares gained 5.7% to trade at $3.8250 on Wednesday.

These analysts made changes to their price targets on Altimmune following earnings announcement.

B. Riley Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.
UBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.
HC Wainwright & Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.

Considering buying ALT stock? Here’s what analysts think:

Read This Next:

Top 2 Tech & Telecom Stocks That May Fall Off A Cliff In Q3

Photo via Shutterstock

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559986600"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559986600\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559986600?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 02:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559986600","market":"us","top_or_hot":-1,"title":"These Analysts Slash Their Forecasts On Altimmune Following Q2 Results","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a></strong> (NASDAQ:ALT) posted a loss  for the second quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.</p>\n<p>“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”</p>\n<p>Altimmune shares gained 5.7% to trade at $3.8250 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Altimmune following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/RILY\">B. Riley</a> Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.</li>\n<li>UBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.</li>\n<li>HC Wainwright &amp; Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.</li>\n</ul>\n<p><strong>Considering buying ALT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"575\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238.png 1108w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Tech &amp; Telecom Stocks That May Fall Off A Cliff In Q3</strong></li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Slash Their Forecasts On Altimmune Following Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Slash Their Forecasts On Altimmune Following Q2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-08-14 02:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a></strong> (NASDAQ:ALT) posted a loss  for the second quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.</p>\n<p>“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”</p>\n<p>Altimmune shares gained 5.7% to trade at $3.8250 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Altimmune following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/RILY\">B. Riley</a> Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.</li>\n<li>UBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.</li>\n<li>HC Wainwright &amp; Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.</li>\n</ul>\n<p><strong>Considering buying ALT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"575\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/13145552/image-238.png 1108w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Tech &amp; Telecom Stocks That May Fall Off A Cliff In Q3</strong></li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/47103330/these-analysts-slash-their-forecasts-on-altimmune-following-q2-results","article_id":"2559986600","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559986600","pubTimestamp":1755111443,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","ALT":"Altimmune, Inc.","BK4599":"减肥药"},"translate_title":"这些分析师在第二季度业绩公布后大幅下调了对Altimmune的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":0.9},"content_text":"Altimmune, Inc. (NASDAQ:ALT) posted a loss  for the second quarter on Tuesday.\nThe company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.\n“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are preparing for an End-of-Phase 2 Meeting with the FDA which will position us well for Phase 3 development. In addition, we look forward to reporting the full 48-week data in the fourth quarter and providing further updates as we continue to advance pemvidutide.”\nAltimmune shares gained 5.7% to trade at $3.8250 on Wednesday.\nThese analysts made changes to their price targets on Altimmune following earnings announcement.\n\nB. Riley Securities analyst Mayank Mamtani maintained Altimmune with a Buy and lowered the price target from $20 to $18.\nUBS analyst Eliana Merle maintained the stock with a Buy and lowered the price target from $26 to $24.\nHC Wainwright & Co. analyst Patrick Trucchio reiterated Altimmune with a Buy and maintained a $12 price target.\n\nConsidering buying ALT stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 2 Tech & Telecom Stocks That May Fall Off A Cliff In Q3\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}